Vistagen receives FDA clearance to begin Phase 2 U.S. trials for menopause treatment

Filed April 28, 2026 · Period ending April 22, 2026 · ~1 min read

Key Changes

• high

  FDA issued Study May Proceed letter for refisolone nasal spray, clearing Phase 2 trials in the U.S. for moderate to severe hot flashes in menopausal women. This non-hormonal treatment builds on earlier exploratory studies in Mexico.

  Item 8.01 verify on EDGAR →
• medium

  Refisolone is a non-systemic, non-hormonal product candidate, differentiating it from traditional hormone replacement therapies for menopause symptoms.

  Press Release verify on EDGAR →